Introduction to Stage Iii Nsclc When To Start Durvalumab
Welcome to our comprehensive guide on Stage Iii Nsclc When To Start Durvalumab. Panelists discuss when to
Stage Iii Nsclc When To Start Durvalumab Comprehensive Overview
Roy Herbst, MD, PhD, reviews the course of treatment for patients with D. Ross Camidge, MD, PhD, discusses the practical considerations for initiating treatment with Neal Sean McCall, MD, Winship Cancer Institute, Emory University, Atlanta, GA, discusses the Impact of radiation dose to immune ...
Dr. Jack West reviews data from ESMO 2017 & the NEJM paper on the PACIFIC trial of
Summary & Highlights for Stage Iii Nsclc When To Start Durvalumab
- Andrea Filippi, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy, presents the final analysis from the
- Dr. Jack West reviews key results of the PACIFIC trial of the immunotherapy agent
- Gina Columbus reports on the FDA approval of
- Dr Paz-Ares speaks with ecancer at ESMO 2017 about the outcomes of patients with unresectable advanced
- Experts in
In summary, understanding Stage Iii Nsclc When To Start Durvalumab gives us a better perspective.
